A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

Clinical trial NCT06829199 · WITHDRAWN

Trial details

NCT number: NCT06829199
Sponsor: Merck Sharp & Dohme LLC
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Early Triple Negative Breast Cancer

Start date: 2025-03-26
Primary completion: 2029-01-18
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.